DPI developer Iconovo has announced that interim CEO Anders Månsson will be the company’s permanent CEO. Månsson was named interim CEO at the end of October 2025, afterJohan Wäborg announced that he would step down. He had previously served as an advisor to Iconovo and has had a long career in the pharmaceutical industry, including positions at Oncoinvent, Lidds, RhoVac, LEO Pharma, and Ferring.
Since Månsson’s arrival at Iconovo, the company has announced the initiation of a feasibility study of its ICOone dry powder nasal device for an unnamed pharmaceutical company and the signing of a letter of intent with Lonza related to development of spray dried formulation of inhaled biologics.
Månsson commented, “I am grateful for the board’s confidence in me in continuing to lead the company. The assignment is clear and involves an initial focus on executing deals around the generic platforms ICOres and ICOpre, as well as the gradual build-up of the reformulation business area in collaboration with strategic partners.”
Chairman of the Board Carl Lindgren said, “With Anders’s background and skills, the board is very happy to have him on board for the task, and now with a more long-term perspective as permanent CEO.”
Read the Iconovo press release
